SPRED2 and colorectal carcinoma: Both in vivo and in vitro experiments have shown that the downregulation and upregulation of METTL3 reduces and enhances the metastatic ability of CRC, respectively, and this regulation is exerted through the METTL3/miR-1246/SPRED2 axis.